Tuesday, May 22, 2012

Brewing Kombucha

Brewing Kombucha



This is not a "normal" Back to the Homestead video, but if you have been following Back to the Homestead (The Walker Homestead Updates) for a year or so, you'll likely have seen some recipe videos that I have posted. Kombucha is an effervescent tea-based beverage that is often consumed for its anecdotal health benefits or medicinal purposes. Growing and making things on the homestead that have medicinal purposes is a trend I'd like to develop in the Back to the Homestead video series and though that starting with a Kombucha recipe would be a great place to start.

If you want to get a starter SCOBY (that stands for "Symbiotic Culture of Bacteria and Yeast"), there are many, many places to go. I got my starter from an eBay seller and have maintained the culture for over two years and will likely for years to come.

Here are some links to try:



Some great books on Kombucha:



The last book called "Wild Fermentation" is not a Kombucha book but is considered by many to be the fermenting "bible."

http://en.wikipedia.org/wiki/Kombucha

ENJOY!

1 comment:

  1. ponatinib research data brings new hope to leukemia patients

    Huntsman Cancer Institute Michael Deininger and Thomas O'Hare and his research team found that an oral medication - ponatinib, standard therapy may be an effective treatment against resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive patients with acute lymphoblastic lymphoma (Ph + ALL). Relevant research results on November 29 published in the "New England Journal of Medicine."

    The Phase I clinical trial in the United States five cancer centers. Studies have shown that in the existing tyrosine kinase inhibitors (TKI) resistance in CML and Ph + AML patients, ponatinib play a highly active. Ponatinib is a drug under development, its research and development program aimed at addressing the limitations of existing treatments. The study was funded by a research and development company ponatinib - ARIAD Pharmaceuticals sponsored proceed. University of Utah Huntsman Cancer Institute, director of hematology and hematologic malignancies Deininger Research Assistant Professor and Professor O'Hare ponatinib for all known mutant BCR-ABL1 are valid.

    Deininger said that, ponatinib can say is currently the strongest existing BCR-ABL1 most effective broad-spectrum drugs, or even completely cover all the approved TKI resistant T315I mutant; results of this study with a larger phase II study of initial data consistency, showed ponatinib in resistant CML and Ph + ALL patients with significant activity, the results showed that these new TKI will increase significantly expand the range of treatments available for personalized cancer treatment brings new hope.


    Medchemexpress Can provide the above product,its website:www.medchemexpress.com



    BAY 61-3606 dihydrochloride
    E-3810
    BAY 61-3606
    Cabozantinib S-malate
    Pazopanib
    Axitinib
    OSI-930
    Cediranib
    MP470
    Motesanib Diphosphate

    ReplyDelete